Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis
Authors:
Open Access
- 15 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 8 (4) , 445-448
Abstract
C3 glomerulopathy (C3G) is characterized by C3 deposits with minimal immunoglobulin deposition caused by alternative complement pathway dysregulation. Unfortunately, no therapeutic intervention has consistently improved outcomes for patients with C3G. Eculizumab, a monoclonal antibody to C5, is currently the only approved complement-specific agent with some efficacy in the treatment of C3 glomerulonephritis (C3GN). Here, we describe a patient with acute crescentic C3GN with no identified complement mutation or family history of renal disease who required dialysis for 6 months. Five months after initiation of eculizumab, she became dialysis independent, showing improvement is possible after adequate time on eculizumab.Keywords
This publication has 24 references indexed in Scilit:
- Eculizumab and recurrent C3 glomerulonephritisPediatric Nephrology, 2013
- Recent insights into C3 glomerulopathyNephrology Dialysis Transplantation, 2013
- New Diagnostic Tests and New Therapies for Glomerular DiseasesBlood Purification, 2013
- Eculizumab for Dense Deposit Disease and C3 GlomerulonephritisClinical Journal of the American Society of Nephrology, 2012
- Clinical features and outcomes of 98 children and adults with dense deposit diseasePediatric Nephrology, 2011
- Allelic Variants of Complement Genes Associated with Dense Deposit DiseaseJournal of the American Society of Nephrology, 2011
- Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of ComplementClinical Journal of the American Society of Nephrology, 2011
- Complement and glomerular disease: new insightsCurrent Opinion in Nephrology and Hypertension, 2011
- Dense Deposit DiseaseClinical Journal of the American Society of Nephrology, 2009
- Management of membranoproliferative glomerulonephritis type II with plasmapheresisJournal of Clinical Apheresis, 2002